A Phase I/IIa trial of CD40.PCA in prostate cancer
Latest Information Update: 04 Oct 2024
Price :
$35 *
At a glance
- Drugs Anti-CD40-HPV-vaccine-LinKinVax (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 04 Oct 2024 New trial record
- 26 Sep 2024 According to an EnnoDC media release, company is planning a pre-IND filing for a Phase I/IIa trial in prostate cancer early 2027.